Previous studies showed the stromal TILs were 10% in ER-positive and HER2-negative subtype, 15% in HER2-positive subtype, and 20% in ER-negative and HER2-negative subtype of breast cancer (42). This evidence concerns the gene ERBB2 and breast carcinoma.